Oral presentation at ESMO Annual Meeting 2021
ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
Science & Medicine
Read more ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
Science & Medicine
Read more ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
Science & Medicine
Read more 
STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news